- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04654468
En studie som utvärderar effekten, säkerheten, farmakokinetiken och farmakodynamiken för Crovalimab hos deltagare med paroxysmal nattlig hemoglobinuri (PNH) som inte tidigare behandlats med komplementhämning (COMMODORE 3)
En fas III, multicenter, enarmsstudie som utvärderar effektiviteten, säkerheten, farmakokinetiken och farmakodynamiken hos Crovalimab hos patienter med paroxysmal nattlig hemoglobinuri (PNH) som inte tidigare behandlats med komplementhämning
This study will enroll participants aged 12 years or older with a body weight ≥ 40 kilograms (kg) diagnosed with PNH who have not been previously treated with complement inhibitor therapy. Approximately 50 participants will be treated with Crovalimab for at least 24 weeks.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
-
Chengdu, Kina, 610041
- West China Hospital, Sichuan University
-
Guangzhou, Kina, 510115
- Guangdong General Hospital
-
Tianjin, Kina, 300052
- Tianjin Medical University General Hospital
-
Tianjin, Kina, 300020
- Institute of Hematology and Hospital of Blood Disease
-
-
Hubei
-
Wuhan, Hubei, Kina, 430022
- Union Hospital Tongji Medical College Huazhong University of Science and Technology
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Body weight ≥ 40 kg at screening
- Willingness and ability to comply with all study visits and procedures
- Documented diagnosis of PNH, confirmed by high sensitivity flow cytometry
- LDH Levels ≥ 2x the ULN at screening
- Participants who have at least four transfusions during 12 months prior to screening (documented in the medical record)
- Presence of one or more of the PNH-related signs or symptoms within 3 months of screening
- Vaccination against Neisseria meningitidis serotypes A, C, W, and Y < 3 years prior to initiation of study treatment (Day 1)
- Vaccination against Haemophilius influenzae type B and Streptococcus pneumonia according to national vaccination recommendations
- For participants receiving other therapies (e.g., immunosuppressants, corticosteroids): stable dose for ≥ 28 days prior to screening and up to the first drug administration
- Adequate hepatic and renal function
- Women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception during the treatment period and for 46 weeks (approximately 10.5 months) after the final dose of crovalimab
- Platelet count ≥30,000 per cubic millimeter (mm^3) at screening
- ANC > 500/microlitres (μl) at screening
Exclusion Criteria:
- Current or previous treatment with a complement inhibitor
- History of allogeneic bone marrow transplantation
- History of Neisseria meningitidis infection within 6 months prior to screening and up to first drug administration
- Known or suspected immune or hereditary complement deficiency
- Known HIV infection with cluster of differentiation 4 (CD4) count < 200 cells/µl within 24 weeks prior to screening
- Infection requiring hospitalization or treatment with IV antibiotics within 28 days prior to screening and up to the first drug administration, or oral antibiotics within 14 days prior to screening and up to the first drug administration
- Active systemic bacterial, viral, or fungal infection within 14 days before first drug administration
- Presence of fever (≥ 38˚C) within 7 days before the first drug administration
- Splenectomy < 6 months before screening
- History of malignancy within 5 years prior to screening and up to the first drug administration
- Pregnant or intending to become pregnant during the study or within 46 weeks (10.5 months) after the final dose of study treatment
- Participation in another interventional treatment study with an investigational agent or use of any experimental therapy within 28 days of screening or within 5 half-lives of that investigational product, whichever is greater
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Crovalimab
Participants will receive a loading series of crovalimab comprised of an intravenous (IV) dose on Day 1, followed by weekly crovalimab subcutaneous (SC) doses for 4 weeks on Week 1 Day 2, then on Weeks 2, 3, and 4. Maintenance SC dosing will begin at Week 5 and will continue Q4W (every 4 weeks) thereafter for a total of 24 weeks of study treatment. After 24 weeks of crovalimab treatment, participants who derive benefit from the drug may continue to receive crovalimab. |
Crovalimab will be administered at a dose of 1000 milligrams (mg) IV (for participants with body weight between 40 and 100 kg) or 1500 mg IV (for participants with body weight ≥ 100 kg) on Week 1 Day 1. On Week 1 Day 2 and on Weeks 2, 3 and 4, it will be administered at a dose of 340 mg SC. For Week 5 and Q4W thereafter, it will be administered at a dose of 680 mg SC (for participants with body weight between 40 and 100 kg) or 1020 mg SC (for participants with body weight ≥ 100 kg). Dosing schedule will be as described above. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Mean Percentage of Participants With Hemolysis Control
Tidsram: From Week 5 up to Week 25
|
A Generalized Estimating Equation (GEE) was used to estimate the population-average percentage of the participants with hemolysis control (measured by lactate dehydrogenase (LDH) ≤1.5 x upper limit of normal (ULN)) from Week 5 to Week 25 taking account of the intra-patient and inter-patient correlation between LDH control statuses across visits. The dependent variable was the binary indicator for hemolysis control. Independent variables are categorical effects of visits, continuous baseline LDH. |
From Week 5 up to Week 25
|
|
Difference in Percentage of Participants With Transfusion Avoidance (TA) From Baseline Through Week 25 and Within 24 Weeks Prior to Screening
Tidsram: 24 Weeks Prior to Screening, Baseline to Week 25
|
TA was defined as participants who were packed red blood cell (pRBC) transfusion-free and did not require transfusion per protocol-specified guidelines. TA within 24 weeks prior to screening was based on the pRBC transfusion history in the medical records. Reported in this outcome measure is the difference in the percentage of participants between "baseline through Week 25" and "within 24 weeks prior to screening". 95% Confidence Interval (CI) for the difference between the percentage of participants with transfusion avoidance between Pre-screening and Post-baseline is calculated using the Newcombe method. Screening= Day -28 to Day -1 and Baseline= Day 1. |
24 Weeks Prior to Screening, Baseline to Week 25
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Förändring över tid i total och fri C5-koncentration
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Andel deltagare med biverkningar (AE)
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Andel deltagare med reaktioner på injektionsstället, infusionsrelaterade reaktioner, överkänslighet och infektioner (inklusive meningokock meningit)
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Andel deltagare med biverkningar (AE) som leder till att studien avbryts med läkemedel
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Trog serumkoncentration av Crovalimab över tid
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Serumkoncentrationer av Crovalimab
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Andel deltagare med anti-drogantikroppar (ADA) mot Crovalimab
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Terminal komplementaktivitet mätt med liposomimmunanalys (LIA)
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Observerat värde i absolut retikulocytantal
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Observerat värde i fritt hemoglobin
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Observerat värde i Haptoglobin
Tidsram: Upp till 7 år
|
Upp till 7 år
|
|
|
Procentuell förändring från baslinjen i absolut retikulocytantal
Tidsram: Baslinje, vecka 25
|
Baslinje, vecka 25
|
|
|
Procentuell förändring från baslinjen i fritt hemoglobin
Tidsram: Baslinje, vecka 25
|
Baslinje, vecka 25
|
|
|
Procentuell förändring från baslinjen i Haptoglobin
Tidsram: Baslinje, vecka 25
|
Baslinje, vecka 25
|
|
|
Percentage of Participants With Breakthrough Hemolysis (BTH)
Tidsram: Baseline, Week 25
|
BTH was defined as at least one new or worsening symptom or sign of intravascular hemolysis (fatigue, hemoglobinuria, abdominal pain, shortness of breath [dyspnea], anemia [hemoglobin < 10 grams per deciliter (g/dL)], major adverse vascular event [MAVE, including thrombosis], dysphagia, or erectile dysfunction) in the presence of elevated LDH ≥2xULN after a prior LDH reduction to ≤1.5xULN from the start of study treatment. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to have experienced a BTH event. Percentages have been rounded off to the first decimal point. |
Baseline, Week 25
|
|
Percentage of Participants With Stabilized Hemoglobin
Tidsram: Baseline, Week 25
|
Stabilized hemoglobin was defined as avoidance of a ≥2 g/dL decrease in hemoglobin level from baseline, in the absence of transfusion. As pre-specified in the SAP participants withdrawing before Week 25 were deemed to not have hemoglobin stabilization. |
Baseline, Week 25
|
|
Change From Baseline in Fatigue in Adults Aged >=18 Years
Tidsram: Baseline, Week 2, Week 5, Week 9, Week 17, Week 25
|
Fatigue was assessed using functional assessment of chronic illness therapy-fatigue (FACIT-F) scale. FACIT-F is a self-assessment questionnaire with a 7-day recall period and 13 items evaluating fatigue and its impact on daily life activities. Items are scored on a response scale that ranges from 0 ("not at all") to 4 ("very much so"). Relevant items are reverse scored, and all the items are summed to create a total score range from 0 to 52, with 0 being the worst possible score and 52 being the best possible score. A higher score indicates low fatigue severity. A positive mean change indicates improvement. FACIT-F was assessed in adult participants only. FACIT-F assessment was unintentionally missed in the Schedule of Activities (SoA) table, which site used to guide the assessments at each timepoint. Therefore, data were not collected at Week 25. |
Baseline, Week 2, Week 5, Week 9, Week 17, Week 25
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Clinical Trials, Hoffmann-La Roche
Publikationer och användbara länkar
Allmänna publikationer
- Roth A, Fu R, He G, Alzahrani H, Chou SC, Hicheri Y, Kazmierczak M, Recova VL, Uchiyama M, Vladareanu AM, Beveridge L, Buatois S, Buri M, Compagno N, Shi D, Balachandran N, Sreckovic S, Scheinberg P. Safety of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Haemoglobinuria (PNH): Pooled Results From the Phase 3 COMMODORE Studies. Eur J Haematol. 2025 Feb;114(2):373-382. doi: 10.1111/ejh.14339. Epub 2024 Nov 13.
- Liu H, Xia L, Weng J, Zhang F, He C, Gao S, Jia J, Chang AC, Lundberg P, Shi J, Sima CS, Sostelly A, Sreckovic S, Xiao Z, Zhang Z, Fu R. Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study. Am J Hematol. 2023 Sep;98(9):1407-1414. doi: 10.1002/ajh.26998. Epub 2023 Jul 8.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- YO42311
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .